MiR-1294 Confers Cisplatin Resistance in Ovarian Cancer Cells by Targeting IGF1R
Overview
General Medicine
Pharmacology
Authors
Affiliations
Background: Dysregulation of miRNAs is critical for chemosensitivity to platinum-based agents in ovarian cancer (OC) which is the most aggressive gynecological cancer. However, the underlying mechanisms of miRNA-regulated platinum resistance in ovarian cancer remain unclear. In this study, we intended to investigate the effect of miR-1294 on platinum-resistant OC.
Methods: The expression of miR-1294 in OC tissues (n = 30) and cell lines was measured by qRT-PCR. Cell transfection was carried out to establish miR-1294 overexpression or knockdown. MTT and clone formation assays were performed to examine proliferation in OC cells. Additionally, wound healing and tumor invasion assays were used to investigate cell migration and invasion, respectively. Finally, the expression of epithelial-to-mesenchymal transition (EMT)-associated proteins was measured in OC cells by western blot.
Results: Our results showed that miR-1294 dysregulation manipulated OC cisplatin resistance through regulating IGF1R. Knockdown of IGF1R decreased SKOVP/DDP cell proliferation, migration, invasion and EMT. Moreover, overexpression of miR-1294 prevented OC cisplatin resistance.
Conclusion: Our results indicated that epigenetic regulation of IGF1R via miR-1294 was essential for cisplatin resistance in OC and provide a new avenue for OC treatment.
Carbone L, Incognito G, Incognito D, Nibid L, Caruso G, Berretta M Clin Transl Oncol. 2025; .
PMID: 39775727 DOI: 10.1007/s12094-024-03837-2.
Yao H, Liu D, Gao F, Li Q, Liu S Arch Med Sci. 2024; 20(4):1249-1267.
PMID: 39439709 PMC: 11493060. DOI: 10.5114/aoms/133038.
Biomarker potential of competing endogenous RNA networks in Polycystic Ovary Syndrome (PCOS).
Heidarzadehpilehrood R, Pirhoushiaran M Noncoding RNA Res. 2024; 9(2):624-640.
PMID: 38571815 PMC: 10988127. DOI: 10.1016/j.ncrna.2024.01.002.
Wilczynski J, Paradowska E, Wilczynska J, Wilczynski M Curr Oncol. 2024; 31(1):229-249.
PMID: 38248100 PMC: 10814576. DOI: 10.3390/curroncol31010015.
Qin X, Wang S J Gastrointest Oncol. 2023; 14(3):1451-1461.
PMID: 37435227 PMC: 10331754. DOI: 10.21037/jgo-23-327.